| Autor: |
Cameron, David A., Stein, Steven |
| Zdroj: |
Nature Clinical Practice Oncology; Sep2008, Vol. 5 Issue 9, p512-520, 9p, 3 Charts, 1 Graph |
| Abstrakt: |
The article explores the effectiveness of lapatinib, an oral receptor tyrosine inhibitor targeting human epidermal growth factor receptor type 2 (HER2) and epidermal growth factor receptor (EGFR), in breast cancer treatment. Lapatinib has an activity in trastuzumab-resistant cell lines based on preclinical data. A lapatinib and capecitabine combination reduced the risk of disease progression in women with HER2-positive advanced breast cancer based on a clinical trial. It discusses the potential benefits of the drug to the adjuvant treatment of cancer. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink